	1	
•	+	

					Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI
Under the Paper	work Reduction Act of 1	985, no persons are	required to respond to a collection of information unless it	centains a valid OMB control number	
	Substitute for	or form 144	9A/PTO	Cor	nplete if Known
	ST	ATEME	TION DISCLOSURE NT BY APPLICANT	Application Number	Continuation of 10/028,547
		(use as ma	ny sheets as necessary)		
			•	Filing Date	July 18, 2003
				First Named Inventor	Jay D. Kranzler
ļ				Group Art Unit	
				Examiner Name	
Sheet	1	of	4 .	Attorney Docket Number	CYPR 100 CIP CON

			U.S. PATENT DOCUM	IENTS	
Examiner Cite Initials* No.1		US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
4/		5,621,142	Mochizuki	04-15-1997	
Y		4,478,836	Mouzin	10-23-1984	
		5,034,541	Bigg	07-23-1991	
			iglehart, III	05-28-2002	
N		6,441,038	Loder, et al.	08-27-2002	
			•		
		<u> </u>	· · · · · · · · · · · · · · · · · · ·		

				1	FOREIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1		Foreign Patent Docum	ent	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office.3		Kind Code ⁵ (if known)			. iguios Appeai	
_		EP	*0,759.299		Eli Lilly & Co.	02-26-1997	<u> </u>	
		FR	*2 752 732		Pierre Fabre Medicament	03-06-1998		
N	u	Pet	WO 95/22521		Asahi Kasei Kabushiki Kaisha	08-24-1995		\top
N)CPPET	WΦ 97/35574		Pierre Fabre Medicament	10-02-1997		
,	t	LPET	-*WD-97/35584_		Eli Lilly & Co.	10-02- 1997		
N	i	UPET	VO 98/08495		Pierre Fabre Medicament	03-05-1998		

Examine	11/20/2	Date	0/ /	
Signature		Considered	7/27/01	/

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Dissen	tuna s	nfue :	rian t	+) inside this box ->
LIGHTS	type 4	- Marx s	ng n t	+) futios fun box>

1	

PTO/SB/08A (10-96 Approved for use through 10/31/99, OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

					Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI
Under the Paperwi	ork Reduction Act of 1	995, no persons are	required to respond to a collection of information unless it	contains a valid OMB control number	
	Substitute for	or form 144	9A/PTO		
•				Cor	nplete if Known
	INF	ORMAT	TION DISCLOSURE	Application Number	Continuation of 10/028,547
l			NT BY APPLICANT		•
	017	A C EIVIEI	II DI AII LIOANI		
		(use as mar	ny sheets as necessary)	•	
	•			Filing Date	July 18, 2003
				First Named Inventor	Jay D. Kranzler
				Group Art Unit	
L				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	CYPR 100 CIP CON

					U.S. PATENT DOCUM	INTS		
Examiner Initials*				US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number		Code 2 (nown)			•	

					FOREIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1		Foreign Patent Docum	ent	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	₹º
		Office.3	Number⁴	Kind Code ⁵ (if known)	95	WIN-DD-111	Figures Appeal	
	V	WP.GT	₩Ó 98/36744		Pierre Fabre Medicament	· 08-27-1998		<u> </u>
٠		PCT~	*WO 99/59593	·	Eli Lilly & Co.	11-25-1999	•	/
•		PCT-	*WO 00/32178		Mueller	06-08-2000	;*	1
N		PCT	WO 01/26623		Laxdale Ltd	04-19-2001	,	1
		PCT	*WO 02/053140		Pharmacia & Upjohn Co.	07-11-2002		1

Examine	n 1 a Vh	Date		
Signature		Considered	9/127/0	φ
				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please to	voe a c	us sion	(+) insíde	e this box	→

		PT	OISBIOBA (10-98	
Approved 1	or use through	10/31/99.	OMB 0851-0031	
stent and Trademark (Office: U.S. DI	PARTMEN	T OF COMMERCE	

Substitute for form 1449A/PTO				Complete if Known			
	STATI	EMENT B	DISCLOSURE Y APPLICANT ets as necessary)	Application Number	Continuation of 10/028,547		
				Filing Date	July 18, 2003		
				First Named Inventor	Jay D. Kranzler		
		•		Group Art Unit			
				Examiner Name			
et	3	of	4	Attorney Docket Number	CYPR 100 CIP CON		

Examiner's Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the relation (book, magazine, journal, serial, symposium, catalog, etc.), date, pagesls), volume-issue number(s), publisher, city and/or country where published ARDID, et al., "Antidepressants and pain," La Lettre de Pharmacologue 13: 8 (1993). Cypress Bioscience, Inc., Investor Fact Sheet, August 2001. DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). "DWIGHT, et al., "An open clinical trial of ventafaxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GGOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders." J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a careport," Med. Drug. J. 37: 10 (2001). NAGAOKA, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and their protective effect against NMDA-induced neurotoxicity," Synapse 31: 87-96 (1999).		
publisher, city and/or country where published ARDID, et al., "Antidepressants and pain," La Lettre de Pharmacologue 13: 8 (1993). Cypress Bioscience, Inc., Investor Fact Sheet, August 2001. DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). *DWIGHT, et al., "An open clinical trial of vaniataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndroms and related disorders," J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a careport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		T
ARDID, et al., "Antidepressants and pain," La Lettre de Pharmacologue 13: 8 (1993). Cypress Bioscience, Inc., Investor Fact Sheet, August 2001. DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). *DWIGHT, et al., "An open clinical trial of venlataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a careport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
Cypress Bioscience, Inc., Investor Fact Sheet, August 2001. DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). *DWIGHT, et al., "An open clinical trial of venlataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). *DWIGHT, et al., "An open clinical trial of venlataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). (GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a careport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000).		
DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). *DWIGHT, et al., "An open clinical trial of venlataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders." J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). *DWIGHT, et al., "An open clinical trial of venlataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders." J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a careport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000).		
*DWiGHT, et al., "An open clinical trial of ventataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin, Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of ventafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
*DWiGHT, et al., "An open clinical trial of ventataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin, Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of ventafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	1	
*DWiGHT, et al., "An open clinical trial of ventataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin, Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a careport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of ventafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
*DWIGHT, et al., "An open clinical trial of venlataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	1	
*DWIGHT, et al., "An open clinical trial of venlataxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	1	
GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 1 (1993). MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). "NINAN, "Use of veniafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniafaxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	1	
MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). "NINAN, "Use of veniafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine" PCT Int'l Appl. 14 (09/28/2000). NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniaraxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	3-20	
NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniaraxine in other psychiatric disorders," Depression Anxiety 125: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	- 1	
NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a carreport," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
report," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of Venlaraxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	1	
report," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of Venlaraxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
report," Med. Drug. J. 37: 10 (2001). *NINAN, "Use of veniaraxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		
*NINAN, "Use of venialaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	e	
NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and	İ	
NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and		_
	7	
	1	
	1	
*NUTT & JOHNSON, "Potential applications of venlafaxine," Rev. Contemp. Pharmacother. 9: 321-331 (1998).	7	~~~

			/		
Examiner's		Date			. /
Signature	1/10/11/	Considered	a/1z	2/0	9
				Vt.	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant to place a check mark here if English language Translation is attached.

Please type	a nitre ei	antaline	de this	hav _>

PTO(SB)08A (10-98 Approved for use through 10/31/99. OMB 0851-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Co	Complete if Known		
	STATE	MENT	N DISCLOSURE BY APPLICANT eets as necessary)	Application Number	Continuation of 10/028,547		
	·	•		Filing Date	July 18, 2003		
		•		First Named Inventor	Jay D. Kranzler		
				Group Art Unit			
			•	Examiner Name ¹			
t	4	of	4	Attorney Docket Number	CYPR 100 CIP CON		

OTHER ART NON PATENT LITERATURE DOCUMENTS Examiner's Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the							
Examiner's	Cite						
Initials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
· · · · · ·		*RAO, "The neuropharmacology of centrally-acting analgesic medications in fibromyalgia," Rheum. Dis. Clin, N. Amer. 28:					
		235-259 (2002).					
ا ر		SHUTO, et al., "(±)-Z-2-(Aminomethyl)-1-phenylcyclopropanecarboximide derivatives as a new prototype of NMDA					
<i> </i> //		receptor antagonists," J. Med. Chem. 38: 2964-2968 (1995).					
V		CHITO					
\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		SHUTO, et al., "(1S,2R)-1-(phenyl-2-[(s)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy," Jpn. J. Pharmacol. 85:					
V(207-213 (2001).					
		SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-(phenyl-2-((S)-1aminopropyl)-N,N-					
И		diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist," J. Med. Chem. 39: 4844-4852 (1996).					
		SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S,2R)-1-					
<i> </i>		phenyl-2-[(r)-1-amino-2-propynyl]-N,N-diethylcyclopropane-carboximide is a novel class of NMDA receptor channel blocker," J. Med. Chem. 41: 3507-3514 (1998).					
ļ							
	'						
	l						

Examiner's	11000	Date	0/1-7/	n U
Signature	111 200	Considered	9/2/1	0 7

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant to place a check mark here if English language Translation is attached.